Vascular Endothelial Growth Factor and Angiogenesis
暂无分享,去创建一个
Bart Landuyt | Ann Hoeben | M. Highley | H. Wildiers | A. V. van Oosterom | B. Landuyt | A. Hoeben | Hans Wildiers | E. D. de Bruijn | Martin S. Highley | Allan T. Van Oosterom | Ernst A. De Bruijn
[1] C. Dinney,et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. , 1995, International archives of allergy and immunology.
[3] J. Isner,et al. Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia , 2001, Circulation.
[4] E C Nice,et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.
[5] S. Rafii,et al. The Id proteins and angiogenesis , 2001, Oncogene.
[6] L. Claesson‐Welsh,et al. VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.
[7] C. Dinney,et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] J. Pouysségur,et al. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. , 2000, The Journal of biological chemistry.
[9] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[10] T. Fojo,et al. p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.
[11] S. Rafii,et al. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.
[12] H. Blau,et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. , 1998, Molecular cell.
[13] J. Isner,et al. Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.
[14] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[15] G. Batist,et al. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. , 2001, Expert review of anticancer therapy.
[16] J. Folkman,et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. , 2001, The Journal of urology.
[17] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[18] S. Soker,et al. Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[19] J. M. Arbeit,et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.
[20] H. Yoshiji,et al. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. , 1997, Cancer research.
[21] P. Hewett,et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. , 2002, Cancer research.
[22] R. Weichselbaum,et al. Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .
[23] M. Post,et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.
[24] S. Fox,et al. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. , 2001, The Lancet. Oncology.
[25] B Landuyt,et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.
[26] K. Alitalo,et al. VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] I. Endo,et al. Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. , 2002, Internal medicine.
[28] M. Aglietta,et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. , 1995, The Journal of clinical investigation.
[29] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[30] M. Shibuya,et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Carbone,et al. Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] S. Rafii,et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] Y. Matsumura,et al. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. , 2002, Oncogene.
[35] S. Ramakrishnan,et al. Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: differential effect on proliferating endothelial cells , 2000, British Journal of Cancer.
[36] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[37] Jacques Landry,et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells , 1997, Oncogene.
[38] J. Wood,et al. Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors , 2004, Cancer and Metastasis Reviews.
[39] R. Paridaens,et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] G. Gasparini,et al. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. , 2001, Critical reviews in oncology/hematology.
[41] R. Crystal,et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. , 1998, Journal of vascular surgery.
[42] M A Moses,et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[43] Ulf Eriksson,et al. Vascular endothelial growth factors VEGF‐B and VEGF‐C , 1997, Journal of cellular physiology.
[44] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[45] L. Wilkinson,et al. Demonstration of lymphatics in human synovial tissue , 2004, Rheumatology International.
[46] K. Alitalo,et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. , 1998, The American journal of pathology.
[47] Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. , 1996, The Journal of clinical endocrinology and metabolism.
[48] S. Oliviero,et al. In Fibroblasts Vegf-D Expression Is Induced by Cell-Cell Contact Mediated by Cadherin-11* , 2001, The Journal of Biological Chemistry.
[49] H. Kawanaka,et al. Von Hippel‐Lindau tumor suppressor and HIF‐1α: new targets of NSAID inhibition of hypoxia‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[50] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[51] J. Isner,et al. Endothelial Progenitor Cell Vascular Endothelial Growth Factor Gene Transfer for Vascular Regeneration , 2002, Circulation.
[52] B. Curry,et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. , 2000, Cancer research.
[53] P. Baker,et al. Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients With Preeclampsia , 1995, Obstetrics and gynecology.
[54] R. Weichselbaum,et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.
[55] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[56] W. Sessa,et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. , 2001, The American journal of pathology.
[57] M. Karkkainen,et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.
[58] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[59] J. M. Arbeit,et al. Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .
[60] T. Lindahl,et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. , 2001, Cancer research.
[61] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[62] Jessica Lo,et al. HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .
[63] C E Griffiths,et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis , 1999, The British journal of dermatology.
[64] M. Gassmann,et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.
[65] J. Keski‐Oja,et al. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. , 2002, The Journal of investigative dermatology.
[66] S. Hirohashi,et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] G. Koehl,et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.
[68] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[69] D. Gospodarowicz,et al. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. , 1994, Growth factors.
[70] Joseph B. Kearney,et al. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. , 2002, Blood.
[71] S. Stacker,et al. The vascular endothelial growth factor family; proteins which guide the development of the vasculature , 1998, International journal of experimental pathology.
[72] I. Greer,et al. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre‐eclampsia , 1997, British journal of obstetrics and gynaecology.
[73] A. Yuan,et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] C. Logothetis,et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] Satoru Koyanagi,et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. , 2003, Cancer research.
[76] V. V. van Hinsbergh,et al. Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[77] A. MacKenzie,et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.
[78] R K Jain,et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.
[79] D. Ruiter,et al. Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1 , 2002, Laboratory Investigation.
[80] S. S. Lee,et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. , 2001, Clinical and experimental rheumatology.
[81] Steven A. Stacker,et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.
[82] R. Busse,et al. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. , 1999, Diabetes.
[83] R Bicknell,et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.
[84] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[85] Masanori Tanaka,et al. Microvessel Morphology and Vascular Endothelial Growth Factor Expression in Human Colonic Carcinoma With or Without Metastasis , 2002, Laboratory Investigation.
[86] A. Mantovani,et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.
[87] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[88] J. Nelson,et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[89] C. Wernstedt,et al. Identification of Vascular Endothelial Growth Factor Receptor-1 Tyrosine Phosphorylation Sites and Binding of SH2 Domain-containing Molecules* , 1998, The Journal of Biological Chemistry.
[90] Paul Martin,et al. Wound Healing--Aiming for Perfect Skin Regeneration , 1997, Science.
[91] M. Feldmann,et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.
[92] R. Jaffe,et al. Angiogenesis in the human female reproductive tract. , 1995, Obstetrical & gynecological survey.
[93] J. Winer,et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.
[94] M. Trikha,et al. Platelets and Cancer: Implications for Antiangiogenic Therapy , 2002, Seminars in thrombosis and hemostasis.
[95] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[96] J. Ware,et al. Therapeutic Angiogenesis in Ischemic Heart Disease , 1999, Thrombosis and Haemostasis.
[97] M. Toi,et al. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.
[98] C. Dinney,et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] G M Tozer,et al. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. , 2000, European journal of cancer.
[100] L. Fabri,et al. Purification and refolding of vascular endothelial growth factor‐B , 2000, Protein science : a publication of the Protein Society.
[101] Cynthia Cohen,et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[102] S. Arii,et al. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma , 2000, Cancer.
[103] P. Campochiaro,et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.
[104] E. Paleolog,et al. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders , 1999, International journal of experimental pathology.
[105] J. Isner,et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. , 1998, Journal of vascular surgery.
[106] T. Ishiwata,et al. Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. , 2002, The Journal of rheumatology.
[107] Peter Bohlen,et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.
[108] H. Fraser,et al. Angiogenesis and its control in the female reproductive system. , 2000, British medical bulletin.
[109] L. Water,et al. VEGF expression by epithelial and stromal cell compartments: resolving a controversy. , 2000, The American journal of pathology.
[110] E. Ingham,et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.
[111] S. Szabó,et al. Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. , 1998, The American journal of physiology.
[112] M. Nomura,et al. Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and Pericytes , 1999, The Journal of Biological Chemistry.
[113] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[114] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[115] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[116] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[117] A. Harris,et al. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[118] U. Hellman,et al. Differential Binding of Vascular Endothelial Growth Factor B Splice and Proteolytic Isoforms to Neuropilin-1* , 1999, The Journal of Biological Chemistry.
[119] G. Stancel,et al. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. , 1996, Cancer research.
[120] G. Watanabe,et al. Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. , 2002, Chest.
[121] J. Breed,et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[123] D. Carbone,et al. Vascular Endothelial Growth Factor Effects on Nuclear Factor-κB Activation in Hematopoietic Progenitor Cells , 2001 .
[124] H. Hutchings,et al. Signal relays in the VEGF system. , 1999, Frontiers in bioscience : a journal and virtual library.
[125] J. Isner,et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[126] S. Soker,et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. , 1998, The Journal of biological chemistry.
[127] N. Ferrara,et al. A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration , 2000, The EMBO journal.
[128] S. Gately. The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.
[129] J. Cherrington,et al. The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation , 2002, Radiation research.
[130] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[131] R. Bing. Myocardial ischemia and infarction: growth of ideas. , 2001, Cardiovascular research.
[132] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[133] R. DuBois,et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[134] D. Collins,et al. Inhibition of angiogenesis by antiestrogens. , 1993, Cancer research.
[135] R. Henriksson,et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] K. Alitalo,et al. Proinflammatory Cytokines Regulate Expression of the Lymphatic Endothelial Mitogen Vascular Endothelial Growth Factor-C* , 1998, The Journal of Biological Chemistry.
[137] S. Fan,et al. Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] R. Stouffer,et al. Angiogenesis in ovarian follicular and luteal development. , 2000, Bailliere's best practice & research. Clinical obstetrics & gynaecology.
[139] L. Presta,et al. The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade. , 1996, The EMBO journal.
[140] I. Zachary. Vascular Endothelial Growth Factor: How It Transmits Its Signal , 1998, Nephron Experimental Nephrology.
[141] C. Meuleman,et al. Angiogenic activity of peritoneal fluid from women with endometriosis. , 1993, Fertility and sterility.
[142] David R. Nadeau,et al. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[143] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[144] Kenneth J. Hillan,et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.
[145] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[146] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[147] Sabita Roy,et al. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor‐toxin conjugate , 1997, International journal of cancer.
[148] J. Cherrington,et al. SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[149] J. Schlessinger,et al. Identification of a novel contactin‐associated transmembrane receptor with multiple domains implicated in protein–protein interactions , 1997, The EMBO journal.
[150] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[151] N. Tamura,et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. , 1998, Circulation.
[152] L. Rubbia‐Brandt,et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients , 2000, International journal of cancer.
[153] D. Gingras,et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[154] Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1993, The New England journal of medicine.
[155] Y. Hirata,et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. , 1997, Genomics.
[156] U. Mirastschijski,et al. Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. , 2002, Human pathology.
[157] Y. Okada,et al. Expression of vascular endothelial growth factor isoforms and their receptors Flt‐1, KDR, and neuropilin‐1 in synovial tissues of rheumatoid arthritis , 2000, The Journal of pathology.
[158] L. Nanney,et al. Cell biology of wound healing. , 1996, International review of cytology.
[159] M. Shibuya,et al. A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.
[160] D. Carbone,et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. , 1999, Journal of immunology.
[161] S. Rodan,et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.
[162] M A Konerding,et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.
[163] E. Keshet,et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.
[164] M. Pla,et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[165] J. Becker,et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.
[166] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[167] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.
[168] M. Gassmann,et al. Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.
[169] Yung‐Chie Lee,et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] G. Semenza,et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.
[171] F. Santilli,et al. Role of Growth Factors in the Development of Diabetic Complications , 2000, Hormone Research in Paediatrics.
[172] J. Caro,et al. Hypoxia-inducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing. , 1998, The Journal of biological chemistry.
[173] J. Isner,et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.
[174] Peter Carmeliet,et al. Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.
[175] F. Selheim,et al. Identification of functional VEGF receptors on human platelets , 2002, FEBS letters.
[176] A J Warner,et al. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. , 2000, The Biochemical journal.
[177] M. Shibuya,et al. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells , 1999, Oncogene.
[178] Shay Soker,et al. Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.
[179] K. Alitalo,et al. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. , 1994, Oncogene.
[180] D. Walsh,et al. Angiogenesis and arthritis. , 1999, Rheumatology.
[181] A. Hsu,et al. The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.
[182] A. Ristimäki,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Differential Hormonal Regulation of Vascular Endothelial Growth Factors VEGF, VEGF-B, and VEGF-C Messenger Ribonucleic Acid Levels in Cultured Human , 2022 .
[183] K. Alitalo,et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. , 2002, The Journal of rheumatology.
[184] G. Strassmann,et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. , 1995, Journal of immunology.
[185] Napoleone Ferrara,et al. Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.
[186] D. Marmé,et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.
[187] A. Harris,et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[188] A. Harris,et al. PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON‐SMALL CELL LUNG CANCER , 1996, The Journal of pathology.
[189] A. Harris,et al. The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis , 2001, The Journal of pathology.
[190] E. Levin,et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. , 1998, The Journal of clinical investigation.
[191] S H Lee,et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. , 2000, The New England journal of medicine.
[192] Shay Soker,et al. Relative effects of VEGF‐A and VEGF‐C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin‐1 , 2002, Journal of cellular biochemistry.
[193] J. Vaillant,et al. Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.
[194] W. Sessa,et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.
[195] R K Jain,et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.
[196] H. Fujii,et al. Correlation of Vascular Endothelial Growth Factor-C Expression with Tumor-Infiltrating Dendritic Cells in Gastric Cancer , 2002, Oncology.
[197] S. Hunt. Technology evaluation: IMC-1C11, ImClone Systems. , 2001, Current opinion in molecular therapeutics.
[198] S. Ylä-Herttuala,et al. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb – on the way to the clinic , 2001, European journal of clinical investigation.
[199] L. Orci,et al. Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.
[200] O. Cussenot,et al. VEGF overexpression in clinically localized prostate tumors and neuropilin‐1 overexpression in metastatic forms , 2000, International journal of cancer.
[201] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[202] J. Pober,et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. , 2000, The American journal of pathology.
[203] W. Parks,et al. Epilysin, a Novel Human Matrix Metalloproteinase (MMP-28) Expressed in Testis and Keratinocytes and in Response to Injury* , 2001, The Journal of Biological Chemistry.
[204] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[205] J. Monson,et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer , 2000, British Journal of Cancer.
[206] Y. Matsumura,et al. TAp63γ (p51A) and dNp63α (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression , 2002, Oncogene.
[207] Barbara Mayer,et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[208] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[209] H. Dvorak,et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.
[210] D. Hallahan,et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.
[211] Y. Sasaki,et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[212] Josef Korinek,et al. Proceedings of the American Society of Clinical Oncology , 1982 .
[213] R K Jain,et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.
[214] D. Papamichael. Prognostic role of angiogenesis in colorectal cancer. , 2001, Anticancer research.
[215] M. Dake,et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.
[216] J. Folkman,et al. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.
[217] R. Ali,et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 , 2002, Gene Therapy.
[218] D. Carbone,et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.
[219] Megumi Baba,et al. Anti‐tumor and anti‐metastatic effects of human‐vascular‐endothelial‐growth‐factor‐neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice , 1998, International journal of cancer.
[220] M. Longaker,et al. Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.
[221] J. Minna,et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.
[222] C. Angeletti,et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. , 1998, European journal of cancer.
[223] Till Acker,et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.
[224] H. Joensuu,et al. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[225] W. Jelkmann,et al. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. , 1999, Human reproduction.
[226] K. Alitalo,et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. , 2000, The American journal of pathology.
[227] A. Giaccia,et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.
[228] J. M. Arbeit,et al. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. , 2000, Cancer research.
[229] F. Dieterlen‐Lièvre,et al. Blood-borne seeding by hematopoietic and endothelial precursors from the allantois. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[230] J. Isner. Myocardial gene therapy , 2002, Nature.
[231] B. Echtenacher,et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. , 1999, Cancer research.
[232] A. Genazzani,et al. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. , 1998, Fertility and sterility.
[233] A. Harris,et al. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. , 2000, Cancer research.
[234] Y. Maehara,et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues , 2000, British Journal of Cancer.
[235] G. Neufeld,et al. VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.
[236] H. Ryan,et al. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.
[237] L. Ellis,et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. , 1998, Cancer research.
[238] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[239] H. Verheul,et al. Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[240] R. Kerbel,et al. Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.
[241] Xuri Li,et al. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. , 2001, The international journal of biochemistry & cell biology.
[242] K. Alitalo,et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[243] L. Aiello,et al. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. , 1999, Diabetes.
[244] F. Bayard,et al. Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.
[245] J C Reed,et al. IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.
[246] H. Dvorak,et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.
[247] H. Dvorak,et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.
[248] Makoto Murakami,et al. Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.
[249] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[250] J. Gallo,et al. Cells designed to deliver anticancer drugs by apoptosis. , 2002, Cancer research.
[251] R. Eisenstein. Angiogenesis in arteries: review. , 1991, Pharmacology & therapeutics.
[252] D. Hanahan,et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.
[253] M. Moses,et al. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. , 2001, Cancer research.
[254] C. Thompson,et al. Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1α nor Sufficient for HIF-1-dependent Target Gene Transcription* , 2002, The Journal of Biological Chemistry.
[255] H. Cai,et al. Cloning and Characterization of Neuropilin-1-Interacting Protein: A PSD-95/Dlg/ZO-1 Domain-Containing Protein That Interacts with the Cytoplasmic Domain of Neuropilin-1 , 1999, The Journal of Neuroscience.
[256] M. Karkkainen,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.
[257] Cherrington,et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.
[258] B. Olffson. Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .
[259] A. Lassar,et al. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. , 1994, Current opinion in cell biology.
[260] K. Seibert,et al. COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.
[261] B Z Levi,et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.
[262] M. Highley,et al. Immuno affinity purification combined with mass spectrometry detection for the monitoring of VEGF isoforms in patient tumor tissue , 2003 .
[263] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[264] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[265] L. Mayo,et al. VRAP Is an Adaptor Protein That Binds KDR, a Receptor for Vascular Endothelial Cell Growth Factor* , 2000, The Journal of Biological Chemistry.
[266] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[267] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[268] K. Alitalo,et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. , 2000, The American journal of pathology.
[269] M. Shibuya,et al. Vascular Endothelial Growth Factor Is Necessary in the Development of Arteriosclerosis by Recruiting/Activating Monocytes in a Rat Model of Long-Term Inhibition of Nitric Oxide Synthesis , 2002, Circulation.
[270] A. Stopeck,et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[271] K Walsh,et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.
[272] M. Droller. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 2000, The Journal of urology.
[273] K. Alitalo,et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia , 1997, Oncogene.
[274] K. Honn,et al. Adhesion molecules and tumor metastasis: an update. , 1994, Invasion & metastasis.
[275] D. Charnock-Jones,et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. , 1996, The Journal of clinical investigation.
[276] K. Alitalo,et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.
[277] R. Stouffer,et al. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. , 1997, Fertility and sterility.
[278] G. Neufeld,et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. , 1993, The Journal of clinical investigation.
[279] S. Chakrabarti,et al. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy , 2000, Diabetes/metabolism research and reviews.
[280] S. Baruchel,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.
[281] G. Stancel,et al. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. , 1999, Molecular endocrinology.
[282] S. Kawashima,et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus , 1999, The British journal of ophthalmology.
[283] M. Shibuya,et al. A single autophosphorylation site on KDR/Flk‐1 is essential for VEGF‐A‐dependent activation of PLC‐γ and DNA synthesis in vascular endothelial cells , 2001, The EMBO journal.
[284] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[285] D. Carbone,et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[286] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[287] T. Sawada,et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma , 1996, Cancer.
[288] D J Mooney,et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. , 2001, Cancer research.
[289] N. Ahn,et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. , 2000, Cancer Research.
[290] G. Zimmerman,et al. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[291] P Lavie,et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. , 1999, Circulation.
[292] H. Esumi,et al. Regulation of vascular endothelial growth factor expression by insulin‐like growth factor‐I in endometrial adenocarcinoma cells , 2000, International journal of cancer.